Evaxion Biotech A/S（以下简称Evaxion）旗下AI-Immunology™平台在二期个性化癌症疫苗临床试验中取得突破性进展，其疫苗靶点预测精准度高达86%。这一数据显著凸显了人工智能技术在肿瘤免疫治疗领域的巨大应用潜力。
该平台通过深度学习算法分析患者个体肿瘤特异性抗原，从而为每位患者定制专属的治疗性疫苗。高达86%的精准度意味着平台能够高效识别真正具有免疫原性的肿瘤靶点，为提升癌症疫苗的临床疗效奠定了坚实的技术基础。
Evaxion Biotech A/S（以下简称Evaxion）旗下AI-Immunology™平台在二期个性化癌症疫苗临床试验中取得突破性进展，其疫苗靶点预测精准度高达86%。这一数据显著凸显了人工智能技术在肿瘤免疫治疗领域的巨大应用潜力。
该平台通过深度学习算法分析患者个体肿瘤特异性抗原，从而为每位患者定制专属的治疗性疫苗。高达86%的精准度意味着平台能够高效识别真正具有免疫原性的肿瘤靶点，为提升癌症疫苗的临床疗效奠定了坚实的技术基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.